This was a key tip I posted on my Naver blog a while back. I need to share it here too, because for those who need it, this could truly be a lifeline.
You need to hear Jane McLelland’s story first.
There was a woman in the UK named Jane McLelland.
She had terminal cervical cancer that had metastasized into leukemia.
When the doctors said there was nothing more they could do, Jane found a new path through self-experimentation, testing on her own body.
The result?
She beat the crap out of the cancer and survived.
Her experience isn’t just some internet myth.
This method was actually formalized by the Care Oncology Clinic (COC) in London, UK, and has now become a legitimate anti-cancer treatment protocol, to the point where there are branches in the US.
Since 2014, this clinic has applied this method to over 1,500 terminal cancer patients, and survival rates significantly increased.
This is the COC Protocol.
The core is a combination of just 4 inexpensive, readily available drugs.
They aren’t conventional chemotherapy drugs, but familiar medications we already know.
However, they are used for cancer treatment in an off-label way, meaning not for their original intended purpose.
No need for a long explanation..
1. Atorvastatin – 40mg twice daily
It’s a cholesterol-lowering drug, but it activates a destructive protein inside cancer cells.
Literally induces the cancer cells to collapse on their own.
2. Metformin – 500mg twice daily
Start with once a day initially, and if there are no issues, increase to twice a day.
It cuts off the energy source that cancer cells love: glucose.
Think of cancer as a monster that grows by eating sugar.
3. Doxycycline – 100mg once daily
Originally an antibiotic, used for acne and parasite treatment.
It blocks the enzymes (matrix metalloproteinases) that cancer cells use to invade normal tissues.
It acts as a kind of shield.
4. Mebendazole – 100mg once daily
A deworming medication.
It destroys the microtubules in cancer cells, preventing their proliferation and causing the cancer cells to self-destruct.
It even attacks tumor-associated macrophages, breaking down the environment favorable for cancer growth.
Why does this combination work?
These four drugs each have their own anti-cancer effects individually, but when used together, the synergy is explosive.
Mebendazole is the core, but the other drugs essentially surround and attack the cancer cells’ metabolism and defense lines from multiple angles.
Inhibits cancer metastasis.
Synergy when combined with existing chemotherapy/radiation therapy.
Promotes cancer cell suicide (apoptosis).
Low side effects and high safety profile.
COC officially stated they use this combination of four specifically for its safety.
Side effects for Mebendazole, for instance, are mild, like abdominal pain, which goes away if you stop taking it.
I need to say more about Metformin separately.
This is more than just a cancer-suppressing drug.
Research on this drug’s potential for “life extension” is ongoing both domestically and internationally.
A team led by Dr. Kim Mi-sook from the Korea Institute of Radiological & Medical Sciences published research showing that Metformin reduces cancer recurrence risk and increases survival rates in patients with liver, pancreatic, colon, and rectal cancers.
https://youtu.be/5vM6O7vw4iI?si=PdY5D4yQJXH2aEhE
Professor Ahn Chul-woo from Yonsei University explained that this drug is not just a blood sugar controller but can also impact vascular health and lifespan extension.
According to the UKPDS study, people who took Metformin for 20 years had a 39% reduction in myocardial infarction and a 36% reduction in overall mortality.
This is not just a “blood sugar drug.”
It cuts off sugar to starve cancer cells, protects blood vessels, slows aging – it’s a life-extending drug.
Summary
These four drugs are cheaper than any expensive anticancer drug, have fewer side effects, can be combined with existing treatments, and there are survival cases not in the hundreds, but in the thousands.
Cancer cells are monsters gone mad with the desire for survival.
The COC Protocol is the strategy: stop feeding the monster (glucose), cut off its growth platform (cholesterol), take away its wall-breaking tools (matrix metalloproteinases), and finally, make it self-destruct.
While this might not be the right solution for everyone, if even one more person can find hope through it, this information needs to be shared.
“The clue to life extension might lie in Metformin.”
This is not just a meme.
Below is a direct statement from Professor Ahn Chul-woo of Yonsei University College of Medicine, Director of the Vascular Metabolism and Aging Research Institute.
Metformin was developed in the 1920s and has been used as a diabetes treatment since the 1950s.
Being an old drug, it is inexpensive and has relatively mild side effects, mostly gastrointestinal issues.
But recently, this drug is gaining attention again.
The reason is simple.
Study results are continuously being published showing that people who take Metformin actually live longer.
In fact, it’s even being discussed as potentially the first drug ever approved for lifespan extension or combating aging.
This drug is not a simple blood glucose regulator.
Metformin lowers blood sugar by improving insulin resistance in muscle and fat tissues.
Furthermore, it improves lipid metabolism, regulates platelet function, and improves vascular endothelial cell function, enhancing vasodilation.
In other words, Metformin is a drug that not only lowers blood sugar but also prevents vascular aging.
According to Professor Ahn, for type 2 diabetes patients, this drug goes beyond merely controlling blood sugar; it is a highly effective agent for maintaining healthy blood vessels.
There is also substantial data supporting this.
The UKPDS study is a large-scale, long-term study that tracked 5,102 diabetic patients in the UK for 20 years.
The results showed that patients taking Metformin had a 32% reduction in all diabetes-related risk, a 39% reduction in myocardial infarction, a 42% reduction in diabetes-related mortality, and a 36% reduction in overall mortality.
Additionally, another UK study involving 180,000 people also found that Metformin users had a 15% lower mortality rate compared to non-users.
Regarding these findings, Dr. Nir Barzilai, Director of the Institute for Aging Research at Albert Einstein College of Medicine in the US, suggested that some people—namely patients who have been taking Metformin for diabetes—may have already been taking a life-extending drug.
In conclusion, it is premature to call Metformin an ‘anti-aging drug’.
However, it has been scientifically proven that this drug is effective in blood sugar control, improving vascular function, preventing cardiovascular diseases, and suppressing the recurrence of some cancers.
In this regard, Metformin holds considerable potential for life extension, and this potential can develop into a larger research topic in the future.
Professor Ahn says.
I am wary of the aging of the mind and wish to minimize the time spent being old.
The small possibility that a clue to life extension could originate from Metformin is something we must make bigger.
– Professor Ahn Chul-woo, Yonsei University College of Medicine –
Related Resources
1. Metabolic Treatment of Cancer (COC Protocol Clinical Application)
Interim results on the informal alternative therapy (COC Protocol) conducted by COC.
The combination of four low-dose existing drugs (Metformin, Atorvastatin, Doxycycline, Mebendazole) significantly improved survival in terminal cancer patients.
Blocks cancer metabolic pathways, multi-target approach, cheaper than high-cost anticancer drugs with lower side effects.
Shows potential for tumor growth inhibition and survival rate improvement.
https://pubmed.ncbi.nlm.nih.gov/33384656/
2. ReDO-Statins as Anticancer Agents
Introduces the mechanism by which statins (including Atorvastatin) affect cancer cell growth signaling and induce cell death (apoptosis).
Indirectly impacts cancer-related pathways like mTOR, Ras, PI3K.
Atorvastatin induces cell death (apoptosis) in specific tumor environments.
More effective in combination therapy than alone. A promising component for off-label anticancer therapy.
https://pubmed.ncbi.nlm.nih.gov/24294566/
3. UKPDS 34 – Metformin and Survival Rate
A 20-year follow-up large-scale long-term study of 5,102 diabetic patients in the UK.
The Metformin group showed a significant reduction in both cardiovascular disease and overall mortality.
Myocardial infarction 39%↓, overall mortality 36%↓, estimated indirect reduction in cancer incidence.
Confirmed function of inhibiting vascular aging in addition to improving insulin sensitivity.
Proves its value not as a simple blood sugar drug, but as a candidate ‘life-extending drug’.
https://pubmed.ncbi.nlm.nih.gov/9742977/
Care Oncology Clinic Official Website (Detailed explanation of COC Protocol)
https://careoncologyclinic.com
Jane McLelland’s Book – How to Starve Cancer (The source explaining the cancer metabolic blockade strategy)
https://www.howtostarvecancer.com/
UKPDS (United Kingdom Prospective Diabetes Study) Official Results
https://www.diabetes.org.uk/professionals/research/research-round-up/ukpds
